Nivolumab (Opdivo®). HTA ID: 23050

Assessment Status Rapid Review Complete
HTA ID 23050
Drug Nivolumab
Brand Opdivo®
Indication In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%.
Assessment Process
Rapid review commissioned 01/08/2023
Rapid review completed 17/08/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab for this indication on the basis of the proposed price relative to currently available therapies.